Afuco™ Anti-Human IL18 ADCC Recombinant Antibody, ADCC Enhanced (CAT#: AFC-388CL)

Figure 1 Mean plasma glucose levels revealed several apparent improvements in glucose control, as determined by reductions in FPG, in a number of patients dosed with placebo and doses of GSK1070806 up to Day 85.

McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., & Gil-Extremera, B. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One, 11(3), e0150018.

Figure 2 With the exception of insulin and C-peptide at one time point (0.25 mg/kg vs placebo on Day 29), there were also no statistically significant effects of GSK1070806 doses on glucose, insulin and C-peptide weighted mean AUC(0–4 hours) over placebo on Days 29, 57, and 85.

McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., & Gil-Extremera, B. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One, 11(3), e0150018.

Figure 3 Assessment of the mean change from baseline shows evidence of a reduction in HbA1c percent up to Day 85 with subjects dosed with GSK1070806 5 mg/kg compared with placebo, although the data are highly variable.

McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., & Gil-Extremera, B. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One, 11(3), e0150018.